677 related articles for article (PubMed ID: 25223734)
1. Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.
Tirode F; Surdez D; Ma X; Parker M; Le Deley MC; Bahrami A; Zhang Z; Lapouble E; Grossetête-Lalami S; Rusch M; Reynaud S; Rio-Frio T; Hedlund E; Wu G; Chen X; Pierron G; Oberlin O; Zaidi S; Lemmon G; Gupta P; Vadodaria B; Easton J; Gut M; Ding L; Mardis ER; Wilson RK; Shurtleff S; Laurence V; Michon J; Marec-Bérard P; Gut I; Downing J; Dyer M; Zhang J; Delattre O;
Cancer Discov; 2014 Nov; 4(11):1342-53. PubMed ID: 25223734
[TBL] [Abstract][Full Text] [Related]
2. The genomic landscape of pediatric Ewing sarcoma.
Crompton BD; Stewart C; Taylor-Weiner A; Alexe G; Kurek KC; Calicchio ML; Kiezun A; Carter SL; Shukla SA; Mehta SS; Thorner AR; de Torres C; Lavarino C; Suñol M; McKenna A; Sivachenko A; Cibulskis K; Lawrence MS; Stojanov P; Rosenberg M; Ambrogio L; Auclair D; Seepo S; Blumenstiel B; DeFelice M; Imaz-Rosshandler I; Schwarz-Cruz Y Celis A; Rivera MN; Rodriguez-Galindo C; Fleming MD; Golub TR; Getz G; Mora J; Stegmaier K
Cancer Discov; 2014 Nov; 4(11):1326-41. PubMed ID: 25186949
[TBL] [Abstract][Full Text] [Related]
3. The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.
Brohl AS; Solomon DA; Chang W; Wang J; Song Y; Sindiri S; Patidar R; Hurd L; Chen L; Shern JF; Liao H; Wen X; Gerard J; Kim JS; Lopez Guerrero JA; Machado I; Wai DH; Picci P; Triche T; Horvai AE; Miettinen M; Wei JS; Catchpool D; Llombart-Bosch A; Waldman T; Khan J
PLoS Genet; 2014 Jul; 10(7):e1004475. PubMed ID: 25010205
[TBL] [Abstract][Full Text] [Related]
4. High-resolution genome-wide copy-number analyses identify localized copy-number alterations in Ewing sarcoma.
Lynn M; Wang Y; Slater J; Shah N; Conroy J; Ennis S; Morris T; Betts DR; Fletcher JA; O'Sullivan MJ
Diagn Mol Pathol; 2013 Jun; 22(2):76-84. PubMed ID: 23628818
[TBL] [Abstract][Full Text] [Related]
5. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
6. Deep Sequencing in Conjunction with Expression and Functional Analyses Reveals Activation of FGFR1 in Ewing Sarcoma.
Agelopoulos K; Richter GH; Schmidt E; Dirksen U; von Heyking K; Moser B; Klein HU; Kontny U; Dugas M; Poos K; Korsching E; Buch T; Weckesser M; Schulze I; Besoke R; Witten A; Stoll M; Köhler G; Hartmann W; Wardelmann E; Rossig C; Baumhoer D; Jürgens H; Burdach S; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Nov; 21(21):4935-46. PubMed ID: 26179511
[TBL] [Abstract][Full Text] [Related]
7. Risk stratification by somatic mutation burden in Ewing sarcoma.
Liu KX; Lamba N; Hwang WL; Niemierko A; DuBois SG; Haas-Kogan DA
Cancer; 2019 Apr; 125(8):1357-1364. PubMed ID: 30602061
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
9. STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma.
Surdez D; Zaidi S; Grossetête S; Laud-Duval K; Ferre AS; Mous L; Vourc'h T; Tirode F; Pierron G; Raynal V; Baulande S; Brunet E; Hill V; Delattre O
Cancer Cell; 2021 Jun; 39(6):810-826.e9. PubMed ID: 33930311
[TBL] [Abstract][Full Text] [Related]
10. The prognostic signature of the somatic mutations in Ewing sarcoma: from a network view.
Zhang Y; Song J; Shi Q; Song X; Shen L; Zhou J; Shao J
Jpn J Clin Oncol; 2019 Jul; 49(7):604-613. PubMed ID: 30927420
[TBL] [Abstract][Full Text] [Related]
11. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53.
van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE
J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828
[TBL] [Abstract][Full Text] [Related]
12. Next steps in Ewing sarcoma (epi-)genomics.
Sannino G; Orth MF; Grünewald TG
Future Oncol; 2017 Jun; 13(14):1207-1211. PubMed ID: 28589731
[No Abstract] [Full Text] [Related]
13. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome.
Tsuda Y; Zhang L; Meyers P; Tap WD; Healey JH; Antonescu CR
Genes Chromosomes Cancer; 2020 Sep; 59(9):525-534. PubMed ID: 32362012
[TBL] [Abstract][Full Text] [Related]
14. Prospective Clinical Genomic Profiling of Ewing Sarcoma:
Ogura K; Elkrief A; Bowman AS; Koche RP; de Stanchina E; Benayed R; Mauguen A; Mattar MS; Khodos I; Meyers PA; Healey JH; Tap WD; Hameed M; Zehir A; Shukla N; Sawyers C; Bose R; Slotkin E; Ladanyi M
JCO Precis Oncol; 2022 Aug; 6():e2200048. PubMed ID: 35952322
[TBL] [Abstract][Full Text] [Related]
15. Ewing sarcoma: a tough road to clinically relevant biomarkers.
Shukla N
Pediatr Blood Cancer; 2015 May; 62(5):741-2. PubMed ID: 25586427
[No Abstract] [Full Text] [Related]
16. An Old Story Retold: Loss of G1 Control Defines A Distinct Genomic Subtype of Esophageal Squamous Cell Carcinoma.
Wang Q; Bai J; Abliz A; Liu Y; Gong K; Li J; Shi W; Pan Y; Liu F; Lai S; Yang H; Lu C; Zhang L; Chen W; Xu R; Cai H; Ke Y; Zeng C
Genomics Proteomics Bioinformatics; 2015 Aug; 13(4):258-70. PubMed ID: 26386145
[TBL] [Abstract][Full Text] [Related]
17. [Functional genomics of Ewing sarcoma].
Grünewald TGP
Pathologe; 2017 Nov; 38(Suppl 2):198-201. PubMed ID: 28849372
[TBL] [Abstract][Full Text] [Related]
18. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma.
Mackintosh C; Ordóñez JL; García-Domínguez DJ; Sevillano V; Llombart-Bosch A; Szuhai K; Scotlandi K; Alberghini M; Sciot R; Sinnaeve F; Hogendoorn PC; Picci P; Knuutila S; Dirksen U; Debiec-Rychter M; Schaefer KL; de Álava E
Oncogene; 2012 Mar; 31(10):1287-98. PubMed ID: 21822310
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and Evaluation of a Class of Compounds Inhibiting the Growth of Stromal Antigen 2 (STAG2)-Mutant Ewing Sarcoma Cells.
Zhang N; Lin KF; Yang C; Peruski S; Pati D; Gilbertson SR
ChemMedChem; 2022 May; 17(9):e202100653. PubMed ID: 35018729
[TBL] [Abstract][Full Text] [Related]
20. Germline Variation and Somatic Alterations in Ewing Sarcoma.
Machiela MJ; Grünewald TGP
Methods Mol Biol; 2021; 2226():3-14. PubMed ID: 33326089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]